Howard Sofen
Overview
Explore the profile of Howard Sofen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armstrong A, Lebwohl M, Warren R, Sofen H, Morita A, Paul C, et al.
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40045918
Background: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for...
2.
McLaren J, Chon Y, Gorski K, Bernstein J, Corren J, Hayama K, et al.
J Allergy Clin Immunol
. 2025 Feb;
PMID: 39956278
Background: Tezepelumab, an mAb inhibiting thymic stromal lymphopoietin, is an upstream-targeted therapy with potential to inhibit multiple pathways in chronic spontaneous urticaria (CSU). Objective: We sought to evaluate tezepelumab efficacy...
3.
Merola J, Ferris L, Sobell J, Sofen H, Osborne J, Vaile J, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):453-462.
PMID: 39918727
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in multiple countries for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. The...
4.
Gooderham M, Mrowietz U, Kadus W, Drda K, Gu H, Vangerow H, et al.
J Invest Dermatol
. 2025 Jan;
PMID: 39848568
Trial Design: This 2-part, double-blinded trial assessed the RORγt inhibitor BI 730357 in plaque psoriasis. Methods: In part 1, patients were randomized 2:2:2:2:1 to 25, 50, 100, and 200 mg...
5.
Simpson E, Hebert A, Browning J, Serrao R, Sofen H, Brown P, et al.
Dermatol Ther (Heidelb)
. 2025 Jan;
15(1):111-124.
PMID: 39777610
Introduction: Tapinarof is a topical aryl hydrocarbon receptor (AhR) agonist in development for the treatment of atopic dermatitis (AD). In two phase 3 trials (ADORING 1 and 2), tapinarof cream...
6.
Stander S, Yosipovitch G, Legat F, Reich A, Paul C, Simon D, et al.
JAMA Dermatol
. 2024 Nov;
161(2):147-156.
PMID: 39602139
Importance: Prurigo nodularis (PN) is a chronic and debilitating skin condition, characterized by intense itch with multiple nodular lesions. Nemolizumab demonstrated significant improvements in itch and skin nodules in adults...
7.
Armstrong A, Lebwohl M, Warren R, Sofen H, Imafuku S, Ohtsuki M, et al.
JAMA Dermatol
. 2024 Nov;
161(1):56-66.
PMID: 39602111
Importance: Safe and effective long-term treatments for moderate to severe plaque psoriasis are needed. Objective: To evaluate the long-term safety and efficacy of deucravacitinib through 3 years (week 148) in...
8.
Korman N, Warren R, Bagel J, Armstrong A, Gooderham M, Strober B, et al.
J Dermatolog Treat
. 2024 Jun;
35(1):2371045.
PMID: 38945549
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo...
9.
A Lio P, Armstrong A, Gutermuth J, Nosbaum A, Sofen H, Garcia Gil E, et al.
Dermatol Ther (Heidelb)
. 2024 Jun;
14(7):1929-1943.
PMID: 38922484
Introduction: Atopic dermatitis (AD) is a chronic inflammatory skin disease for which signs and symptoms have a negative impact on a patient's quality of life (QoL) and mental health. Here,...
10.
Lebwohl M, Warren R, Sofen H, Imafuku S, Paul C, Szepietowski J, et al.
Br J Dermatol
. 2024 Jan;
190(5):668-679.
PMID: 38226713
Background: In the phase III POETYK PSO-1 and PSO-2 trials, deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, was well tolerated and efficacious over 1 year in patients with...